Literature DB >> 32060662

Model Averaging in Viral Dynamic Models.

Antonio Gonçalves1, France Mentré2, Annabelle Lemenuel-Diot3, Jérémie Guedj2.   

Abstract

The paucity of experimental data makes both inference and prediction particularly challenging in viral dynamic models. In the presence of several candidate models, a common strategy is model selection (MS), in which models are fitted to the data but only results obtained with the "best model" are presented. However, this approach ignores model uncertainty, which may lead to inaccurate predictions. When several models provide a good fit to the data, another approach is model averaging (MA) that weights the predictions of each model according to its consistency to the data. Here, we evaluated by simulations in a nonlinear mixed-effect model framework the performances of MS and MA in two realistic cases of acute viral infection, i.e., (1) inference in the presence of poorly identifiable parameters, namely, initial viral inoculum and eclipse phase duration, (2) uncertainty on the mechanisms of action of the immune response. MS was associated in some scenarios with a large rate of false selection. This led to a coverage rate lower than the nominal coverage rate of 0.95 in the majority of cases and below 0.50 in some scenarios. In contrast, MA provided better estimation of parameter uncertainty, with coverage rates ranging from 0.72 to 0.98 and mostly comprised within the nominal coverage rate. Finally, MA provided similar predictions than those obtained with MS. In conclusion, parameter estimates obtained with MS should be taken with caution, especially when several models well describe the data. In this situation, MA has better performances and could be performed to account for model uncertainty.

Entities:  

Keywords:  infectious diseases; model averaging; model selection; viral dynamics

Mesh:

Substances:

Year:  2020        PMID: 32060662     DOI: 10.1208/s12248-020-0426-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  33 in total

1.  Parameter identifiability and estimation of HIV/AIDS dynamic models.

Authors:  Hulin Wu; Haihong Zhu; Hongyu Miao; Alan S Perelson
Journal:  Bull Math Biol       Date:  2008-02-05       Impact factor: 1.758

2.  Towards a quantitative understanding of the within-host dynamics of influenza A infections.

Authors:  Andreas Handel; Ira M Longini; Rustom Antia
Journal:  J R Soc Interface       Date:  2009-05-27       Impact factor: 4.118

3.  Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Authors:  Julie Bertrand; Emmanuelle Comets; France Mentre
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

4.  Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.

Authors:  Hoai-Thu Thai; France Mentré; Nicholas H G Holford; Christine Veyrat-Follet; Emmanuelle Comets
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-12-08       Impact factor: 2.745

5.  Model-based dose finding under model uncertainty using general parametric models.

Authors:  José Pinheiro; Björn Bornkamp; Ekkehard Glimm; Frank Bretz
Journal:  Stat Med       Date:  2013-12-03       Impact factor: 2.373

6.  Dynamics of influenza virus infection and pathology.

Authors:  Roberto A Saenz; Michelle Quinlivan; Debra Elton; Shona Macrae; Anthony S Blunden; Jennifer A Mumford; Janet M Daly; Paul Digard; Ann Cullinane; Bryan T Grenfell; John W McCauley; James L N Wood; Julia R Gog
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

7.  Model selection versus model averaging in dose finding studies.

Authors:  Kirsten Schorning; Björn Bornkamp; Frank Bretz; Holger Dette
Journal:  Stat Med       Date:  2016-05-25       Impact factor: 2.373

8.  Introduction to modeling viral infections and immunity.

Authors:  Alan S Perelson; Ruy M Ribeiro
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

9.  A comprehensive hepatitis C viral kinetic model explaining cure.

Authors:  E Snoeck; P Chanu; M Lavielle; P Jacqmin; E N Jonsson; K Jorga; T Goggin; J Grippo; N L Jumbe; N Frey
Journal:  Clin Pharmacol Ther       Date:  2010-05-12       Impact factor: 6.875

10.  Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling.

Authors:  Anne-Gaëlle Dosne; Martin Bergstrand; Kajsa Harling; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-10-11       Impact factor: 2.745

View more
  6 in total

1.  Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.

Authors:  Guillaume Lingas; Kyle Rosenke; David Safronetz; Jérémie Guedj
Journal:  PLoS Comput Biol       Date:  2021-01-07       Impact factor: 4.475

2.  SARS-CoV-2 viral dynamics in non-human primates.

Authors:  Antonio Gonçalves; Pauline Maisonnasse; Flora Donati; Mélanie Albert; Sylvie Behillil; Vanessa Contreras; Thibaut Naninck; Romain Marlin; Caroline Solas; Andres Pizzorno; Julien Lemaitre; Nidhal Kahlaoui; Olivier Terrier; Raphael Ho Tsong Fang; Vincent Enouf; Nathalie Dereuddre-Bosquet; Angela Brisebarre; Franck Touret; Catherine Chapon; Bruno Hoen; Bruno Lina; Manuel Rosa Calatrava; Xavier de Lamballerie; France Mentré; Roger Le Grand; Sylvie van der Werf; Jérémie Guedj
Journal:  PLoS Comput Biol       Date:  2021-03-17       Impact factor: 4.475

3.  Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.

Authors:  Guillaume Lingas; Nadège Néant; Alexandre Gaymard; Drifa Belhadi; Gilles Peytavin; Maya Hites; Thérèse Staub; Richard Greil; Jose-Artur Paiva; Julien Poissy; Nathan Peiffer-Smadja; Dominique Costagliola; Yazdan Yazdanpanah; Florent Wallet; Amandine Gagneux-Brunon; France Mentré; Florence Ader; Charles Burdet; Jérémie Guedj; Maude Bouscambert-Duchamp
Journal:  J Antimicrob Chemother       Date:  2022-04-27       Impact factor: 5.758

4.  Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies.

Authors:  Mélanie Guhl; François Mercier; Carsten Hofmann; Satish Sharan; Mark Donnelly; Kairui Feng; Wanjie Sun; Guoying Sun; Stella Grosser; Liang Zhao; Lanyan Fang; France Mentré; Emmanuelle Comets; Julie Bertrand
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-09-16       Impact factor: 2.410

5.  Comparative assessment of viral dynamic models for SARS-CoV-2 for pharmacodynamic assessment in early treatment trials.

Authors:  Akosua A Agyeman; Tao You; Phylinda L S Chan; Dagan O Lonsdale; Christoforos Hadjichrysanthou; Tabitha Mahungu; Emmanuel Q Wey; David M Lowe; Marc C I Lipman; Judy Breuer; Frank Kloprogge; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2022-08-30       Impact factor: 3.716

6.  Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load.

Authors:  Antonio Gonçalves; Julie Bertrand; Ruian Ke; Emmanuelle Comets; Xavier de Lamballerie; Denis Malvy; Andrés Pizzorno; Olivier Terrier; Manuel Rosa Calatrava; France Mentré; Patrick Smith; Alan S Perelson; Jérémie Guedj
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.